MX2016013434A - Inhibidores potentes y selectivos del virus de la hepatitis c. - Google Patents

Inhibidores potentes y selectivos del virus de la hepatitis c.

Info

Publication number
MX2016013434A
MX2016013434A MX2016013434A MX2016013434A MX2016013434A MX 2016013434 A MX2016013434 A MX 2016013434A MX 2016013434 A MX2016013434 A MX 2016013434A MX 2016013434 A MX2016013434 A MX 2016013434A MX 2016013434 A MX2016013434 A MX 2016013434A
Authority
MX
Mexico
Prior art keywords
virus
hepatitis
potent
selective inhibitors
compounds
Prior art date
Application number
MX2016013434A
Other languages
English (en)
Spanish (es)
Inventor
Junxing Shi
Steven J Coats
Richard Anthony Whitaker
Raymond F Schinazi
Amblard Franck
Rosario Mcbrayer Tamara
Zhang Hongwang
Zhou Longhu
Original Assignee
Cocrystal Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocrystal Pharma Inc filed Critical Cocrystal Pharma Inc
Publication of MX2016013434A publication Critical patent/MX2016013434A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2016013434A 2014-04-15 2015-04-15 Inhibidores potentes y selectivos del virus de la hepatitis c. MX2016013434A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461980016P 2014-04-15 2014-04-15
PCT/US2015/025903 WO2015160907A2 (en) 2014-04-15 2015-04-15 Potent and selective inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
MX2016013434A true MX2016013434A (es) 2017-03-03

Family

ID=54324704

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013434A MX2016013434A (es) 2014-04-15 2015-04-15 Inhibidores potentes y selectivos del virus de la hepatitis c.

Country Status (14)

Country Link
US (1) US9926295B2 (enExample)
EP (1) EP3131892A4 (enExample)
JP (1) JP2017513852A (enExample)
KR (1) KR20170002407A (enExample)
CN (1) CN106661004A (enExample)
AU (1) AU2015247706A1 (enExample)
BR (1) BR112016023833A2 (enExample)
CA (1) CA2945514A1 (enExample)
IL (1) IL248318A0 (enExample)
MX (1) MX2016013434A (enExample)
PH (1) PH12016502039A1 (enExample)
RU (1) RU2016144076A (enExample)
SG (1) SG11201608587QA (enExample)
WO (1) WO2015160907A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
CN105530933B (zh) 2013-07-17 2018-12-11 百时美施贵宝公司 用于治疗hcv的包含联苯衍生物的组合产品
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN112203652A (zh) * 2018-05-09 2021-01-08 共晶制药公司 用于治疗hcv的组合疗法
CN109456375B (zh) * 2018-12-11 2019-10-22 枣庄学院 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2242752T3 (pl) * 2008-02-13 2012-12-31 Bristol Myers Squibb Co Imidazolilobifenyloimidazole jako inhibitory wirusa zapalenia wątroby typu c
EP2393815A4 (en) * 2009-02-06 2012-11-21 Rfs Pharma Llc PURIN NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR THE TREATMENT OF CANCER AND VIRUS INFECTIONS
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2616461A4 (en) * 2010-08-26 2014-03-26 Rfs Pharma Llc POTENTIVE AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS
WO2012048421A1 (en) * 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
EP2635570B1 (en) * 2010-11-01 2017-12-13 RFS Pharma, LLC. Novel specific hcv ns3 protease inhibitors

Also Published As

Publication number Publication date
JP2017513852A (ja) 2017-06-01
AU2015247706A1 (en) 2016-10-27
SG11201608587QA (en) 2016-11-29
EP3131892A2 (en) 2017-02-22
WO2015160907A3 (en) 2016-12-01
PH12016502039A1 (en) 2017-01-09
US20170029407A1 (en) 2017-02-02
CA2945514A1 (en) 2015-10-22
RU2016144076A (ru) 2018-05-16
IL248318A0 (en) 2016-11-30
BR112016023833A2 (pt) 2017-10-10
WO2015160907A2 (en) 2015-10-22
CN106661004A (zh) 2017-05-10
US9926295B2 (en) 2018-03-27
EP3131892A4 (en) 2017-09-20
KR20170002407A (ko) 2017-01-06

Similar Documents

Publication Publication Date Title
JOP20210109A1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PH12018550150A1 (en) Elimination of hepatitis b virus with antiviral agents
WO2012027712A3 (en) Potent and selective inhibitors of hepatitis c virus
ZA201606320B (en) Human plasma kallikrein inhibitors
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
NZ703064A (en) Inhibitors of hepatitis c virus
UA117518C2 (uk) 6-конденсовані гетероарилдигідропіримідини для лікування та профілактики зараження вірусом гепатиту b
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12018502015A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
MX2018011786A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue.
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
PH12016502039A1 (en) Potent and selective inhibitors of hepatitis c virus
NZ733313A (en) Indole derivatives as dengue viral replication inhibitors
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MY185672A (en) Mono-or di-substituted indole derivatives as dengue viral replication inhibitors
MY197383A (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors